Ending “Buy-And-Bill” in Oncology: The Question is How, Not If
This article was originally published in RPM Report
Executive Summary
The public policy debate over affordability of cancer care is approaching consensus on the need to end the “buy-and-bill” model for chemotherapy. How, and how fast, are the key remaining questions. For biopharma manufacturers, there are good reasons to embrace the change.
You may also be interested in...
Who’s Afraid Of Payment Reform? CMS Cardiac Bundle Shows How Changes Can Be Positive For Rx
Medicare’s proposed demonstration project to change payments in Medicare Part B aside, when it comes to ideas for payment and delivery reform, prescription drugs should do pretty well. CMS’ new proposal to bundle cardiac payments is a timely case in point.
J.P. Morgan Notebook, Jan. 13: Drug Costs, Gilead, Valeant, Allergan/Actavis, Bristol
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the 2015 J.P. Morgan Healthcare Conference in San Francisco. Pricing talk dominates day two, and companies weigh in on the fallout from failed M&A.
Cutting Cost in Oncology: MD Anderson Tries Episode-Based Payments
At the Institute of Medicine’s National Cancer Policy Forum workshop, MD Anderson Cancer Center gave an update on its pilot to bundle payments using an episode-based model. The approach is less about the cost of drugs—and more about the overall cost of treatment.